Sökning: WFRF:(Van Cutsem E) >
Phase 3 Trial of Lu...
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
-
- Strosberg, J. (författare)
- H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.
-
- El-Haddad, G. (författare)
- H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.
-
- Wolin, E. (författare)
- Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
-
visa fler...
-
- Hendifar, A. (författare)
- Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
-
- Yao, J. (författare)
- Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
-
- Chasen, B. (författare)
- Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
-
- Mittra, E. (författare)
- Stanford Univ, Sch Med, Stanford, CA 94305 USA.
-
- Kunz, P. L. (författare)
- Stanford Univ, Sch Med, Stanford, CA 94305 USA.
-
- Kulke, M. H. (författare)
- Dana Farber Canc Inst, Boston, MA 02115 USA.
-
- Jacene, H. (författare)
- Dana Farber Canc Inst, Boston, MA 02115 USA.
-
- Bushnell, D. (författare)
- Univ Iowa, Iowa City, IA USA.
-
- O'Dorisio, T. M. (författare)
- Univ Iowa, Iowa City, IA USA.
-
- Baum, R. P. (författare)
- Zentralklin, Bad Berka, Germany.
-
- Kulkarni, H. R. (författare)
- Zentralklin, Bad Berka, Germany.
-
- Caplin, M. (författare)
- Royal Free Hosp, London, England.
-
- Lebtahi, R. (författare)
- Hop Beaujon, Clichy, France.
-
- Hobday, T. (författare)
- Mayo Clin Coll Med, Rochester, MN USA.
-
- Delpassand, E. (författare)
- Excel Diagnost Imaging Clin, Houston, TX USA.
-
- Van Cutsem, E. (författare)
- Univ Hosp, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium.
-
- Benson, A. (författare)
- Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA.
-
- Srirajaskanthan, R. (författare)
- Kings Coll Hosp NHS FDN Trust, London, England.
-
- Pavel, M. (författare)
- Charite, Berlin, Germany.
-
- Mora, J. (författare)
- Hosp Univ Bellvitge, Barcelona, Spain.
-
- Berlin, J. (författare)
- Vanderbilt Univ, Med Ctr, Nashville, TN USA.
-
- Grande, E. (författare)
- Hosp Univ Ramon & Cajal, Madrid, Spain.
-
- Reed, N. (författare)
- Beatson Oncol Ctr, Glasgow, Lanark, Scotland.
-
- Seregni, E. (författare)
- Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy.
-
- Öberg, Kjell (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Sierra, M. Lopera (författare)
- Adv Accelerator Applicat USA, New York, NY USA.
-
- Santoro, P. (författare)
- Adv Accelerator Applicat USA, New York, NY USA.
-
- Thevenet, T. (författare)
- Adv Accelerator Applicat, St Genis Pouilly, France.
-
- Erion, J. L. (författare)
- Adv Accelerator Applicat USA, New York, NY USA.
-
- Ruszniewski, P. (författare)
- Hop Beaujon, Clichy, France.
-
- Kwekkeboom, D. (författare)
- Erasmus MC, Rotterdam, Netherlands.
-
- Krenning, E. (författare)
- Erasmus MC, Rotterdam, Netherlands.
-
visa färre...
-
H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. (creator_code:org_t)
- 2017
- 2017
- Engelska.
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 376:2, s. 125-135
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (Lu-177)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either Lu-177-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (Lu-177-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. RESULTS At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the Lu-177-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the Lu-177-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the Lu-177-Dotatate group and 26 in the control group (P = 0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the Lu-177-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. CONCLUSIONS Treatment with Lu-177-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the Lu-177-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials. gov number, NCT01578239; EudraCT number 2011-005049-11.)
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Strosberg, J.
-
El-Haddad, G.
-
Wolin, E.
-
Hendifar, A.
-
Yao, J.
-
Chasen, B.
-
visa fler...
-
Mittra, E.
-
Kunz, P. L.
-
Kulke, M. H.
-
Jacene, H.
-
Bushnell, D.
-
O'Dorisio, T. M.
-
Baum, R. P.
-
Kulkarni, H. R.
-
Caplin, M.
-
Lebtahi, R.
-
Hobday, T.
-
Delpassand, E.
-
Van Cutsem, E.
-
Benson, A.
-
Srirajaskanthan, ...
-
Pavel, M.
-
Mora, J.
-
Berlin, J.
-
Grande, E.
-
Reed, N.
-
Seregni, E.
-
Öberg, Kjell
-
Sierra, M. Loper ...
-
Santoro, P.
-
Thevenet, T.
-
Erion, J. L.
-
Ruszniewski, P.
-
Kwekkeboom, D.
-
Krenning, E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Allmänmedicin
- Artiklar i publikationen
-
New England Jour ...
- Av lärosätet
-
Uppsala universitet